Form 4: Elevation Oncology Director Julie Cherrington Acquires 35,000 Stock Options
SEC Form 4 Filing
Director Julie Cherrington acquired 35,000 stock options in Elevation Oncology, Inc. on June 13, 2024.
Summary
- On June 13, 2024, Julie M Cherrington, a director of Elevation Oncology, Inc., acquired 35,000 stock options.
- The exercise price of these options is $3.35.
- The options vest 100% on the one-year anniversary of the grant date, contingent on continued service to the Issuer.
- The options expire on June 12, 2034.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine filing indicating a director's acquisition of stock options, which is neither overtly positive nor negative.
Positives
- The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future prospects.
Future Outlook
The document does not contain any specific forward-looking statements or guidance.
Industry Context
This is a standard SEC Form 4 filing, reflecting a change in beneficial ownership of securities. It is common for directors and officers of publicly traded companies to receive stock options as part of their compensation.
Stakeholder Impact
- The acquisition of stock options by a director could have a slightly positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 06/13/2024 | Date of transaction: Julie Cherrington acquired 35,000 stock options. |
| 06/13/2025 | Vesting date: 100% of the stock options vest, subject to continued service. |
| 06/12/2034 | Expiration date: Stock options expire. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.